Co-Diagnostics, Inc. (CODX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CODX POWR Grades
- Value is the dimension where CODX ranks best; there it ranks ahead of 98.08% of US stocks.
- CODX's strongest trending metric is Sentiment; it's been moving up over the last 178 days.
- CODX's current lowest rank is in the Growth metric (where it is better than 0.06% of US stocks).
CODX Stock Summary
- For CODX, its debt to operating expenses ratio is greater than that reported by only 4.62% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for CO-DIAGNOSTICS INC; that's greater than it is for just 9.39% of US stocks.
- As for revenue growth, note that CODX's revenue has grown -65.04% over the past 12 months; that beats the revenue growth of just 2.99% of US companies in our set.
- Stocks that are quantitatively similar to CODX, based on their financial statements, market capitalization, and price volatility, are VMAR, IPGP, MRCY, FSLR, and IPA.
- Visit CODX's SEC page to see the company's official filings. To visit the company's web site, go to www.codiagnostics.com.
CODX Valuation Summary
- CODX's EV/EBIT ratio is -2.9; this is 144.27% lower than that of the median Healthcare stock.
- Over the past 69 months, CODX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for CODX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CODX | 2023-03-17 | 2.2 | 0.7 | -5.4 | -2.9 |
| CODX | 2023-03-16 | 2.7 | 0.8 | -6.4 | -3.7 |
| CODX | 2023-03-15 | 1.7 | 0.7 | 5.9 | 0.5 |
| CODX | 2023-03-14 | 1.7 | 0.7 | 6.1 | 0.7 |
| CODX | 2023-03-13 | 1.6 | 0.7 | 5.8 | 0.4 |
| CODX | 2023-03-10 | 1.7 | 0.7 | 5.8 | 0.4 |
CODX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CODX has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
- CODX's asset turnover comes in at 1.285 -- ranking 10th of 186 Medical Equipment stocks.
- ALGN, IART, and XENT are the stocks whose asset turnover ratios are most correlated with CODX.
The table below shows CODX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.285 | 0.835 | 2.189 |
| 2021-03-31 | 1.529 | 0.792 | 2.398 |
| 2020-12-31 | 1.631 | 0.777 | 2.360 |
| 2020-09-30 | 1.671 | 0.740 | 2.026 |
| 2020-06-30 | 1.636 | 0.746 | 2.230 |
| 2020-06-30 | 1.636 | 0.654 | 1.725 |
CODX Price Target
For more insight on analysts targets of CODX, see our CODX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.50 | Average Broker Recommendation | 1.67 (Moderate Buy) |
CODX Stock Price Chart Interactive Chart >
CODX Price/Volume Stats
| Current price | $1.91 | 52-week high | $7.13 |
| Prev. close | $1.90 | 52-week low | $1.87 |
| Day low | $1.88 | Volume | 161,500 |
| Day high | $2.04 | Avg. volume | 103,702 |
| 50-day MA | $2.88 | Dividend yield | N/A |
| 200-day MA | $3.75 | Market Cap | 59.06M |
Co-Diagnostics, Inc. (CODX) Company Bio
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Latest CODX News From Around the Web
Below are the latest news stories about CO-DIAGNOSTICS INC that investors may wish to consider to help them evaluate CODX as an investment opportunity.
Co-Diagnostics, Inc. to Host Booth at 10th Gene Quantification Event in Munich, Germany, March 20-22Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 10th Gene Quantification Event held March 20-24 at the Technical University of Munich. Dr. Carl Wittwer, Chair of the Company's Scientific Advisory Board (SAB) will also be presenting at the event. |
Q4 2022 Co-Diagnostics Inc Earnings CallQ4 2022 Co-Diagnostics Inc Earnings Call |
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue EstimatesCo-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -113.33% and 74.53%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Co-Diagnostics, Inc. Reports Full Year 2022 Financial ResultsCo-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2022. |
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 EARNINGS RELEASE DATE AND WEBCASTCo-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2022 results on Thursday, March 16, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. |
CODX Price Returns
| 1-mo | N/A |
| 3-mo | -25.39% |
| 6-mo | -36.75% |
| 1-year | -70.48% |
| 3-year | -81.72% |
| 5-year | -18.38% |
| YTD | -24.21% |
| 2022 | -71.78% |
| 2021 | -3.98% |
| 2020 | 938.87% |
| 2019 | -39.92% |
| 2018 | -43.56% |
Continue Researching CODX
Want to see what other sources are saying about Co-Diagnostics Inc's financials and stock price? Try the links below:Co-Diagnostics Inc (CODX) Stock Price | Nasdaq
Co-Diagnostics Inc (CODX) Stock Quote, History and News - Yahoo Finance
Co-Diagnostics Inc (CODX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...